Analyst Rating Update on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : 12 brokerage houses believe that Boston Scientific Corporation (BSX) is a Strong Buy at current levels. 3 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Boston Scientific Corporation (BSX). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 20 Wall Street Analysts endorse the stock as a Buy with a rating of 1.63.

Boston Scientific Corporation (BSX) : Currently there are 18 street experts covering Boston Scientific Corporation (BSX) stock. The most bullish and bearish price target for the stock is $30 and $20 respectively for the short term. The average price target of all the analysts comes to $26.03. The estimated standard deviation from the target is $2.96.

For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Jefferies maintains its rating on Boston Scientific Corporation (NYSE:BSX). As per the latest information, the brokerage house raises the price target to $24 per share from a prior target of $21. The shares have been rated Hold. The rating by the firm was issued on July 29, 2016.


Boston Scientific Corporation (NYSE:BSX): The stock opened at $24.17 on Wednesday but the bulls could not build on the opening and the stock topped out at $24.22 for the day. The stock traded down to $23.75 during the day, due to lack of any buying support eventually closed down at $23.84 with a loss of -1.37% for the day. The stock had closed at $24.17 on the previous day. The total traded volume was 6,151,457 shares.

Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.